Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Chk1 versus Cdc25: chking one's levels of cellular proliferation.

Lam MH, Rosen JM.

Cell Cycle. 2004 Nov;3(11):1355-7. Epub 2004 Nov 10. Review.

PMID:
15483403
2.

Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism.

Uto K, Inoue D, Shimuta K, Nakajo N, Sagata N.

EMBO J. 2004 Aug 18;23(16):3386-96. Epub 2004 Jul 22.

4.

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?

Goto H, Izawa I, Li P, Inagaki M.

Cancer Sci. 2012 Jul;103(7):1195-200. doi: 10.1111/j.1349-7006.2012.02280.x. Epub 2012 Apr 23. Review.

5.

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.

Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ.

Science. 1997 Sep 5;277(5331):1497-501.

6.

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.

Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H.

J Biol Chem. 2000 Feb 25;275(8):5600-5.

7.

ATR, Claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage.

Sørensen CS, Syljuåsen RG, Lukas J, Bartek J.

Cell Cycle. 2004 Jul;3(7):941-5. Epub 2004 Jul 13.

PMID:
15190204
8.

p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest.

Wang XQ, Stanbridge EJ, Lao X, Cai Q, Fan ST, Redpath JL.

Radiat Res. 2007 Dec;168(6):706-15.

PMID:
18088187
9.

HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability.

Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ.

Nat Cell Biol. 2007 Apr;9(4):391-401. Epub 2007 Mar 25.

10.
11.

Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition.

Shimuta K, Nakajo N, Uto K, Hayano Y, Okazaki K, Sagata N.

EMBO J. 2002 Jul 15;21(14):3694-703.

12.

NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling.

Sørensen CS, Melixetian M, Klein DK, Helin K.

Cell Cycle. 2010 Feb 1;9(3):450-5. Epub 2010 Feb 3.

PMID:
20090422
13.

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H.

Int J Cancer. 2006 Dec 15;119(12):2784-94.

14.

Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1.

Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnica-Worms H, Enoch T.

Nature. 1998 Oct 1;395(6701):507-10.

PMID:
9774107
15.
16.

Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.

Takagaki K, Katsuma S, Kaminishi Y, Horio T, Tanaka T, Ohgi T, Yano J.

Genes Cells. 2005 Feb;10(2):97-106.

17.

Checkpoint kinase inhibitors: a patent review (2009 - 2010).

Lainchbury M, Collins I.

Expert Opin Ther Pat. 2011 Aug;21(8):1191-210. doi: 10.1517/13543776.2011.586632. Epub 2011 May 20. Review.

PMID:
21599421
18.

SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase.

Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, Harper JW.

Genes Dev. 2003 Dec 15;17(24):3062-74. Epub 2003 Dec 17.

Supplemental Content

Support Center